NCT04707547 (RFA) is a Phase 4 clinical trial of immunotherapy with Nivolumab in Liver Cancer, sponsored by Taipei Medical University WanFang Hospital.

Who is sponsoring NCT04707547?

NCT04707547 is sponsored by Taipei Medical University WanFang Hospital.

What drugs are being tested in NCT04707547?

Interventions in NCT04707547: immunotherapy with Nivolumab, Radiofrequency Ablation.

What condition does NCT04707547 study?

NCT04707547 studies Liver Cancer.

Is NCT04707547 still recruiting?

NCT04707547 is currently completed. Last updated 13 January 2021.

Last reviewed 2021-01-13 · How we verify

NCT04707547: RFA

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Immune Profile and Prognosis of Malignant Liver Tumors With Radiofrequency Ablation (RFA) Therapy

Completed Phase 4 Last updated 13 January 2021

What this trial tests

Phase 4 trial testing immunotherapy with Nivolumab in Liver Cancer in 5 participants. Completed in 23 July 2020.

Timeline

16 October 2019

Primary endpoint
23 July 2020

23 July 2020

Quick facts

Lead sponsor	Taipei Medical University WanFang Hospital
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	5
Start date	16 October 2019
Primary completion	23 July 2020
Estimated completion	23 July 2020
Sites	1 location across Taiwan

Drugs / interventions tested

immunotherapy with Nivolumab — full drug profile →
Radiofrequency Ablation

Conditions studied

Liver Cancer — all drugs for Liver Cancer →

Sponsor

Taipei Medical University WanFang Hospital

Who can join

20 and older, any sex, with Liver Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Clearing potential intrahepatic metastasis to prevent early recurrence after liver cancer treatment, there are no effective interventions so far. For secondary metastatic cancer, only the lesions visible under ultrasound can be used, one by one for local ablation and chemotherapy, but people may develop new tumor lesions. Therefore, the treatment of potential tumors and recurrent tumors after ablation is a very important clinical issue.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Clinical application status and prospect of the combined anti-tumor strategy of ablation and immunotherapy.
Yin L, Li XY, Zhu LL, Chen GL, et al · · 2022 · cited 15× · PMID 36131929 · DOI 10.3389/fimmu.2022.965120
A comprehensive review about the utilization of immune checkpoint inhibitors and combination therapy in hepatocellular carcinoma: an updated review.
Sharafi F, Hasani SA, Alesaeidi S, Kahrizi MS, et al · · 2022 · cited 9× · PMID 35999569 · DOI 10.1186/s12935-022-02682-z
Combining energy-based focal ablation and immune checkpoint inhibitors: preclinical research and clinical trials.
Jiang M, Fiering S, Shao Q. · · 2023 · cited 7× · PMID 37251920 · DOI 10.3389/fonc.2023.1153066
Immune profiling in oncology: bridging the gap between technology and treatment.
Ravi N, Tye GJ, Dhaliwal SS, Musa MY, et al · · 2025 · cited 3× · PMID 40856894 · DOI 10.1007/s12032-025-03002-x

Verify or expand the search:

Other recruiting trials for Liver Cancer

Currently open trials in the same condition.

NCT07295275 — Safety and Efficacy of Transarterial ICG Fluorescence-Guided Laparoscopic Anatomical Liver Resection · recruiting
NCT07410494 — Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
NCT07295340 — Diagnostic Accuracy of Folate-Targeted NIR-II Carbon Dots for Ex Vivo HCC Detection · recruiting
NCT07504367 — Large Language Models Assist in Tumor MDT · NA · recruiting
NCT07447050 — Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial · Phase 2 · recruiting

Other Taipei Medical University WanFang Hospital trials

Trials by the same sponsor.

NCT07401017 — The Effects of Rosuvastatin on Running Training Adaptation and Safety · NA · not yet recruiting
NCT07293442 — Pelvic Floor Muscle Exercise for Lower Urinary Tract Symptoms After Surgery for Benign Prostatic Hyperplasia. · NA · recruiting
NCT07150182 — Shared Decision-Making for Families in Critical Dialysis Initiation · NA · not yet recruiting
NCT06834425 — Efficacy of NSAID Peritendinous Injection for Acute Tendinitis · NA · active not recruiting
NCT06862297 — Prospective Study Between Polysomnography (PSG) and Novel Ultrasonic Jaw Tracking Device in Patients with Sleep Apnea · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04707547 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Taipei Medical University WanFang Hospital
Last refreshed: 13 January 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04707547.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing